The tumor mutation burden, which reflects the neoantigenic diversity of a tumor, might also be used to predict the benefit of immunotherapy related to the high anti-PD1 response rate in DNA mismatch repair deficient (dMMR) tumors. Here, PDCD1 is linked to neoplasm.